Adjuvant platinum-based chemotherapy for early stage cervical cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 11, 2016, Pages

  Falcetta, Frederico S ^a,b   Medeiros, Lídia Rf ^c   Edelweiss, Maria I ^c   Pohlmann, Paula R ^d   Stein, Airton T ^b   Rosa, Daniela D ^b,e  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e HOSPITAL MOINHOS DE VENTO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; FLUOROURACIL; PLATINUM DERIVATIVE;

ADJUVANT THERAPY; ADVERSE DRUG REACTION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; FEMALE; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); UTERINE CERVIX CANCER; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; HYSTERECTOMY; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; HYSTERECTOMY; NEOPLASM STAGING; PLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 85000869344     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005342.pub4     Document Type: Review

References (110)

1. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of Clinical Oncology 2000;18(8):1606-13. [3374303; PMID: 10764420]
2. Cancer Research UK. A prospective randomised trial of adjuvant chemotherapy in node positive early stage carcinoma of the cervix - Protocol CE3005. UK Clinical Trials Register 2001. [3374305]
3. Sun W, Wang T, Shi F, Wang J, Hui B, Zhang Y, et al. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy. BMC Cancer 2015;15:353. [4446711]
4. Tattersall MH, Ramirez C, Coppleson M. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases. Gynecologic Oncology 1992;46(2):176-81. [3374307; PMID: 1500019]
5. Argenta PA, Ghebre R, Dusenbery KE, Chen MD, Judson PL, Downs LS, et al. Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up. European Journal of Gynaecological Oncology 2006;27(3):231-5. [3374309; PMID: 16800247]
6. Blohmer JU, Paepke S, Bohmer D, Ernhardt B, Sehouli J, Elling D, et al. Adjuvant chemotherapy of cervix carcinoma--results of a phase II study. Zentralblatt fur Gynakologie 2001;123(5):286-91. [3374311]
7. Buxton EJ, Saunders N, Blackledge GR, Kelly K, Redman CW, Monaghan J, et al. The potential for adjuvant therapy in early-stage cervical cancer. Cancer Chemotherapy and Pharmacology 1990;26(Suppl 26):S17-21. [3374313; PMID: 1693315]
8. Chatterjee K, Mondal SK, Sarkar P. Adjuvant chemotherapy in the management of cervical cancers - A prospective randomized study. European Journal of Cancer. 2013; Vol. 49:S721-S722. [4446713]
9. Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecologic Oncology 1996;61:3-10. [3374315; PMID: 8626113]
10. Dimpfl T, Stumpfe M, Baltzer J, Genz T. Results of adjuvant chemotherapy of operated high risk cervix carcinoma. Geburtshilfe Frauenheilkd 1996;56(10):517-9. [3374317; PMID: 9036063]
11. Frigerio L, Busci L, Rabaiotti E, Mariani A. Adjunctive radiotherapy after radical hysterectomy in high risk early stage cervical carcinoma. Assessment of morbidity and recurrences. European Journal of Gynaecological Oncology 1994;15(2):132-7. [3374319; PMID: 8005143]
12. Hansgen G, Dunst J. Adjuvant radio- and chemotherapy in cervix carcinoma. Zentralblatt fur Gynakologie 2001;123(5):280-5. [3374321; PMID: 11449621]
13. Hansgen G, Kuhnt T, Pigorsch S, Strauss H, Dunst J. Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study. Strahlentherapie und Onkologie 2002;178(2):71-7. [3374323; PMID: 11942040]
14. Harrand R, Sadozye AH, Siddiqui N, Burton K, Shanbhag S, Davis J, et al. Audit of adjuvant cisplatin +/-vaginal brachytherapy following radical hysterectomy and nodal dissection for cervical cancer. International Journal of Gynecological Cancer. 2013; Vol. 23:231. [4446715]
15. Ikeda M, Teshima K, Noda K, Yamagata S, Sugawa T, Okamura S, et al. Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association. Gan To Kagaku Ryoho 1994;21(12):1967-74. [3374325]
16. Iwasaka T, Kamura T, Yokoyama M, Matsuo N, Nakano H, Sugimori H. Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of adjuvant radiotherapy. Obstetrics and Gynecology 1998;91(6):977-81. [3374327; PMID: 9611008]
17. Kato T, Yakushiji M, Yamabe T, Sugimori H, Hidaki T, Tsukamoto N, et al. A multicenter cooperative study on supplementary chemotherapy of uterocervical cancer. The Kyushu UFT Study Group of Uterocervical Cancer. Gan To Kagaku Ryoho 1994;21(8):1221-7. [3374329]
18. Kemnitz T, Krafft W, Glaser F, Schirmer A. Efficacy of adjuvant chemotherapy in metastasizing cervix carcinoma. A pilot study. Zentralblatt fur Gynakologie 1991;113(13):777-81. [3374331; PMID: 1927129]
19. Killackey MA, Boardman L, Carroll DS. Adjuvant chemotherapy and radiation in patients with poor prognostic stage Ib/IIa cervical cancer. Gynecologic Oncology 1993;49(3):377-9. [3374333; PMID: 8314541]
20. Kim YB, Cho JH, Keum KC, Lee CG, Seong J, Suh CO, et al. on current chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. Gynecologic Oncology 2007;104(1):58-63. [3374335; PMID: 16919718]
21. Koh WJ, Panwala K, Greer B. Adjuvant therapy for high-risk, early stage cervical cancer. Seminars in Radiation Oncology 2000;10(1):51-60. [3374337; PMID: 10671659]
22. Lahousen M, Haas J. Adjuvant chemotherapy in radical surgery of cervix cancer. Zentralblatt fur Gynakologie 1990;112(11):707-13. [3374339; PMID: 2399774]
23. Lahousen M, Haas J, Pickel H, Hackl A, Kurz C, Ogris H, et al. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial. Gynecologic Oncology 1999;73(2):196-201. [3374341; PMID: 10329034]
24. Lai CH, Lin TS, Soong YK, Chen HF. Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma. Gynecologic Oncology 1989;35(2):193-8. [3374343; PMID: 2478428]
25. Lai CH, Tang SG, Chang TC, Tseng CJ, Chou HH, Huang KG, et al. Implications of a failed prospective trial of adjuvant therapy after radical hysterectomy for stage Ib-IIa cervical carcinoma with pelvic node metastases. Changgeng Yi Xue Za Zhi 1998;21(3):291-9. [3374345; PMID: 9849010]
26. Lai CH, Hong JH, Hsueh S, Ng KK, Chang TC, Tseng CJ, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer 1999;85(7):1537-46. [3374347]
27. Lee TS, Kang SB, Kim YT, Park BJ, Kim YM, Lee JM, et al. Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study. International Journal of Radiation Oncology, Biology, Physics 2013;86(2):304-10. [4446717]
28. Lin H, ChangChien CC, Chang SY, Leung SW. Survival advantages and complications of adjuvant therapy in early-stage cervical cancer with pelvic node metastasis. Changgeng Yi Xue Za Zhi 1998;21(4):383-90. [3374349]
29. Lin H, ChangChien CC, Huang EY, Eng HL, Huang CC. The role of radical surgery followed by adjuvant therapy for high-risk early-stage cervical carcinoma patients with pelvic lymph node metastasis. European Journal of Obstetrics, Gynecology and Reproductive Biology 2000;93(1):85-90. [3374351; MEDLINE: PMID: 11000510]
30. Linghu H, Xu XR, Mei YY, Tang JY, Tang LD, Sun T. Short-time analysis for adjuvant chemotherapy in patients with early- stage bulky cervical carcinoma. Chinese Journal for Cancer Research 2003;15(2):144-8. [3374353; Embase]
31. Liu J, Huang H, Li JD, Li YF, Huang X, Zhang YN, et al. Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma-interim analysis of a 3-arm randomized control study. International Journal of Gynecological Cancer. 2014; Vol. 24 (Supplement 4):7-8. [4446719]
32. Lu KH, Burke TW. Early cervical cancer. Current Treatment Options in Oncology 2000;1(2):147-55. [3374355; PMID: 12057052]
33. McCaffrey R, Bahtiyar M, Kohorn EI, Chambers JT, Schwartz PE, Chambers SK. Neoadjuvant and adjuvant chemotherapy of cervical cancer: Mature results of the phase 2 PBM-PFU protocol. International Journal of Gynecological Cancer 2011;21:535-44. [4446721]
34. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New England Journal of Medicine 1999;340(15):1137-43. [3374357; PMID: 10202164]
35. Morton GC, Thomas GM. Does adjuvant chemotherapy change the prognosis of cervical cancer?. Current Opinions in Obstetrics and Gynecology 1996;8(1):17-20. [3374359; MEDLINE: PMID: 8777252]
36. Mossa B, Framarino ML, Napolitano C, Marziani R, Imperato F, Marzetti L. Does adjuvant chemotherapy improve the prognosis of cervical carcinoma with lymph-node metastasis? A long-term follow-up. European Journal of Gynaecologic Oncology 2003;24(1):33-40. [3374361; MEDLINE: PMID: 12691314]
37. EORTC-55954, COSA, EU-98061, NSGO-CC-9502, MRC-CE04 A randomised phase III study of chemotherapy and radiotherapy vs. radiotherapy alone as adjuvant treatment to patients with node positive stages IB or IIA cervix cancer. http://www.controlled-trials.com/mrct/trial/391321/MRC-CE04. [3374363]
38. Nakamura K, Satoh T, Takei Y, Nagao S, Sekiguchi I, Suzuki M. Analysis of the effect of adjuvant radiotherapy on outcome and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors. Gynecologic Oncology. 2014; Vol. 133 (Supplement 1):61-2. [4446723]
39. Ng HT, Yuan CC, Kan YY, Ho ES, Yen MS, Chao KC. An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases. Archives of Gynecology and Obstetrics 1995;256(1):1-4. [3374365; PMID: 7726648]
40. Park TK. Adjuvant therapy in cervical cancer patients with high risk factors. Yonsei Medical Journal 1997;38(5):255-60. [3374367; MEDLINE: 9409188]
41. Park TK, Kim SN, Kwon JY, Mo HJ. Postoperative adjuvant therapy in early invasive cervical cancer patients with histopathologic high-risk factors. International Journal of Gynecological Cancer 2001;11(6):475-82. [3374369; PMID: 11906552]
42. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Kim YS, ET AL. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. Journal of Gynecologic Oncology 2012;23(4):226-34. [4446725]
43. Pu J, Qin SS, Ding JX, Zhang Y, Yu CH, Li T, et al. A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery. Journal of Cancer Research and Clinical Oncology 2013;139(4):703-8. [4446727]
44. Richter P. About the value of adjuvant chemotherapy in advanced cervical cancer. First results of a prospective randomised study (author's transl). Archiv für Geschwulstforschung 1982;52(2):117-22. [3374371; PMID: 7049112]
45. Rogers L, Siu SS, Luesley D, Bryant A, Dickinson HO. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database of Systematic Reviews 2012, Issue 5. [4446729; DOI: 10.1002/14651858.CD007583.pub3]
46. Roth SL, Nitz U, Mosny D. The value of adjuvant radio- or chemotherapy after primary surgical therapy of cervix cancer. 1. Adjuvant radiotherapy of cervix cancer. Gynakologe 1994;27(2):89-95. [3374373; PMID: 8039748]
47. Rushdan MN, Tay EH, Khoo-Tan HS, Lee KM, Low JH, Ho TH, et al. Tailoring the field and indication of adjuvant pelvic radiation for patients with FIGO stage Ib lymph nodes-negative cervical carcinoma following radical surgery based on the GOG score - A pilot study. Annals of the Academy of Medicine, Singapore 2004;33(4):467-72. [3374375; 15329758]
48. Russell AH. Adjuvant postoperative radiation: what size target?. Gynecologic Oncology 1995;58(1):1-3. [3374377; PMID: 7789872]
49. Ryu HS, Chun M, Chang KH, Chang HJ, Lee JP. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecologic Oncology 2005;96(2):490-5. [3374379; PMID: 15661240]
50. Schwarz JK, Wahab S, Grigsby PW. Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients. International Journal of Radiation Oncology, Biology, Physics 2011;81(5):1258-63. [4446731]
51. Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, et al. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Annals of Oncology 2012;23(9):2259-64. [4446733]
52. Shimizu Y. Chemotherapy in the management of advanced or high risk cervical cancer. Gan To Kagaku Ryoho 1995;22(9):1152-62. [3374381; MEDLINE: PMID: 7661566]
53. Shu P, Shen Y, Zhao Y, Xu F, Qiu M, Li Q, et al. A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors. Medical Oncology 2015;32(11):247. [4446735]
54. Sivanesaratnam V, Sen DK, Jayalakshmi P. Adjuvant cytotoxic chemotherapy following Wertheim radical hysterectomy for cervical cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology 1987;27(3):231-3. [3374383; PMID: 2449159]
55. Sivanesaratnam V, Jayalakshmi P. Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage IB cervical cancer. Cancer 1989;64(4):798-800. [3374385; PMID: 2501019]
56. Sivanesaratnam V. Adjuvant chemotherapy in "high risk" patients after Wertheim hysterectomy -10-year survivals. Annals Academy of Medicine Singapore 1998;27(5):622-6. [3374387; PMID: 9919328]
57. Strauss HG, Kuhnt T, Laban C, Puschmann D, Pigorsch S, Dunst J, et al. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlentherapie und OnkologieStrahlenther Onkol 2002;178(7):378-85. [3374389; PMID: 12163992]
58. Wada K, Koyama M, Iijima Y, Inagaki M, Hirota Y, Hongo J, et al. Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer. Nippon Sanka Fujinka Gakkai Zasshi 1995;47(3):244-8. [3374391]
59. Wang X, Shen Y, Zhao Y, Li Z, Gou H, Cao D, et al. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial. European Journal of Surgical Oncology 2015;41(8):1082-8. [4446737]
60. Watanabe Y, Nakai H, Shimaoka M, Tobiume T, Tsuji I, Hoshiai H. Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. International Journal of Clinical Oncology 2006;11(4):309-13. [3374393; PMID: 16937305]
61. Wen H, Liu T. Treatment results of adjuvant chemotherapy for patients with intermediate-risk cervical cancer. International Journal of Gynecological Cancer. 2013; Vol. 23:806. [4446739]
62. Wertheim MS, Hakes TB, Doghestani AN, Nori D, Smith DH, Lewis JL Jnr. A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. Journal of Clinical Oncology 1985;3(7):912-6. [3374395]
63. Wolfson AH, Varia MA, Moore D, Rao GG, Gaffney DK, Erickson-Wittmann BA, et al. ACR Appropriateness Criteria role of adjuvant therapy in the management of early stage cervical cancer. Gynecologic Oncology 2012;125(1):256-62. [4446741]
64. Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R et, al Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report. International Journal of Oncology 2004;24(5):1175-9. [3374397; PMID: 15067339]
65. Yessaian A, Magistris A, Burger RA, Monk BJ. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecologic Oncology 2004;94(1):61-6. [3374399; PMID: 15262120]
66. Yoon H, Cha J, Kim G, Chung Y, Kim Y. The long-term follow-up result of extended field radiation therapy for uterine cervical cancer with positive para-aortic lymph nodes: Does the addition of chemotherapy have survival benefit?. International Journal of Radiation Oncology, Biology, Physics. 2014; Vol. 90:S479. [4446743]
67. Zanetta G, Colombo A, Milani R, Placa F, Mangioni C. Long-term results of sequential postoperative treatment with vincristine, bleomycin, mitomycin c, cis-platin and radiotherapy after surgery for high-risk patients with cervical carcinoma stage IB-IIA. International Journal of Gynecological Cancer 1995;5(1):40-4. [3374401; PMID: 11578451]
68. Zhang N, Zheng H, Gao Y. The effectiveness and safety of adjuvant chemotherapy in patients with intermediate-risk early stage cervical cancer after radical hysterectomy. International Journal of Gynecological Cancer. 2012; Vol. 22:E800. [4446745]
69. Zola P, Landoni F, Torri W, Buda A, Mazzola S. Randomised controlled trial of adjuvant treatment in early invasive cervical cancer [abstract]. International Journal of Gynecological Cancer 2003;13 Suppl 1:5-6. [3374403]
70. Ryu SY, Koh W. Radiation therapy with or without chemotherapy in patients with stage I or stage II cervical cancer who previously underwent surgery. www.ClinicalTrials.gov; NCT01101451. [3374405]
71. Hong J-H. Cisplatin based chemoradiation v.s radiotherapy for cervical cancer and with clinically defined good prognosis. www.ClinicalTrials.gov; NCT00846508. [3374407]
72. Liu J, Huang H. A multicenter trial of benefits of adding post-surgery chemotherapy for cervical cancer. www.ClinicalTrials.gov; NCT00806117. [3374409]
73. Adobe Adobe Photoshop CS3 extended (2007). Adobe Systems Incorporated, 2007.
74. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. British Journal of Cancer 1995;72:511-8.
75. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. International Journal of Gynaecology and Obstetrics 2003;83(Suppl 1):41-78.
76. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008285]
77. National Cancer Institute. National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0). http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
78. Curtin JP, Shapiro F. Adjuvant therapy in gynecologic malignancies. Ovarian, cervical, and endometrial cancer. Surgical Oncology Clinics of North America 1997;6(4):813-30. [MEDLINE: PMID: 9309095]
79. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2001.
80. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
81. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncology 2014;15(1):23-34.
82. Ganz PA. Quality of life and the patient with cancer: Individual and policy implications. Cancer 1994;74:1445.
83. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012. Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, 2013.
84. Green JA, Kirwan JJ, Tierney J, Vale CL, Symonds PR, Fresco LL, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD002225.pub2]
85. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
86. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration 2011, issue Version 5.1:www.cochrane-handbook.org.
87. Ho CM, Chien TY, Huang SH, Wu CJ, Shih BY, Chang SC. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecologic Oncology 2004;93(2):458-64. [MEDLINE: PMID: 15099962]
88. Holtz DO, Dunton C. Traditional management of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America 2002;29:645-87.
89. Im SS, Monk BJ. New developments in the treatment of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America 2002;29(4):659-72.
90. Kinney WK, Alvarez RD, Reid GC, Schray MF, Soong SJ, Morley GW, et al. Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study. Gynecologic Oncology 1989;34:258-62.
91. Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treatment Reviews 2003;29:471-88.
92. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman and Hall, 1989.
93. Moher D, Pham D, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
94. Monk BJ, Cha DS, Walker JL, Burger RA, Ramsinghani NS, Manetta A, et al. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecologic Oncology 1994;54:4-9.
95. Surveillance EaERSP. SEER Public-Use 1973-2001. National Cancer Institute. National Cancer Institute, 2004.
96. Nitz U, Roth SL, Mosny D. The value of adjuvant radio- or chemotherapy after primary surgical therapy of cervix cancer. 2. Adjuvant chemotherapy of cervix cancer. Der Gynäkologe 1994;27(2):95-8. [MEDLINE: PMID: 8039749]
97. Pan American Health Organisation. Regional Core Health Data Initiative. Epidemiological Bulletin 2003;24:14-5.
98. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
99. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. International Journal of Gynaecology and Obstetrics 2009;105(2):107-8.
100. Perez CA, Grigsby PW, Castro Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of treatment time and timing of brachytherapy on outcome of radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1995;32:1275-88.
101. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
102. South Australian Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortalityand survival, 1977-2000. Incidence and mortality, 2000. Adelaide: Openbook Publishers, 2001.
103. South Australian Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortality and survival 1977 to 2001. Incidence and mortality 2001. Analysed by type and geographical location. Twenty-five years of data. Adelaide: South Australian Cancer Registry. Epidemiology Branch, 2001.
104. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
105. Sloan JA, Cella D, Frost M. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clinic Proceedings 2002;77:367.
106. College Station, TX: StataCorp LP. StataCorp. Stata Statistical Software: Release 9. College Station, TX: StataCorp LP, 2005.
107. Thomas GM. Adjuvant therapy after primary surgery for stage I-IIA carcinoma of the cervix. Journal of the National Cancer Institute Monograph 1996;21:77-86.
108. Rosa DD, Medeiros LRF, Bozzetti MC, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant chemotherapy for early stage cervix cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005342]
109. Rosa DD, Medeiros LRF, Edelweiss EI, Bozzetti MC, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD005342.pub2]
110. Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD005342.pub3]